Abstract
AI is ushering in a significant paradigm shift across gene and cell therapies (G&CTs), advancing the field away from conventional, trial-and-error treatments toward precision molecular corrections. Although could treat a wide variety of diseases, these complex, living therapeutics raise enormous safety and manufacturing concerns such as genotoxicity, insertional mutagenesis, immunogenicity and extreme batch-to-batch heterogeneity. To address the high-stakes clinical translation while promoting safety, you must dismantle the “black-box” dilemma by utilizing Explainable AI (XAI) frameworks such as SHAP and LIME or glass-box based modeling to ensure biological traceability and regulatory compliance. Even more, AI maximizes biomanufacturing through real-time Process Analytical Technology (PAT), unsupervised anomaly detection, and predictive cold-chain logistics. In order to deploy these algorithmic tools successfully, we need validation protocols with continuous monitoring for model drift; inclusive multi-ethnic datasets to eliminate systemic bias; and adaptive regulatory mechanisms.

This publication has 45 references indexed in Scilit: